Sanofi Pasteur Set To Ship Japan’s First Foreign Hib Vaccine
This article was originally published in PharmAsia News
The head of France-based Sanofi Pasteur said Japan's first foreign-made vaccine for hemophilus influenza type B is expected to be on the market by December. The drug is notable for being the first vaccine licensed by a multinational drug maker to be sold in Japan. Sanofi President Wayne Pisano said strict Japanese approval requirements had delayed the vaccine being allowed there even as it was available in other countries. The infectious disease affects children under 5 with meningitis and pneumonia. Japan expects to receive about 500,000 doses of the vaccine each year. The company make
You may also be interested in...
AstraZeneca's research head admits that half dose approach was a lucky mistake - but one that could boost the vaccine's effectiveness and supplies. The US regulator may not be persuaded, however.
The FAST 01 feasibility trial is evaluating a modification to Varian’s ProBeam particle accelerator that enables ultra-high dose radiation to treat cancer.
HBW Insight speaks to new Global Self-Care Federation chair and Bayer CH chief Heiko Schipper about the role that self-care can play in alleviating pressure on national health care systems, the importance of self-care's scientific credentials and of maintaining supply chain continuity during the coronavirus pandemic.